An unpredictable tsunami is approaching!

According to World Health Organization, “Antimicrobial resistance (AMR) is the ability of a microorganism (like bacteria, viruses, and some parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it” As a result, common life-saving treatments like caesareans will be potentially fatal, infections persist and may spread to others.

Read more


Superbugs are attacking from within hospitals!

Hospital-acquired infections or HAI’s are classified as infections a patient may contract while being treated for an unrelated issue in hospital or healthcare facility. Patients who contract HAI’s are often immune-compromised making them more susceptible to opportunistic bacteria causing infection and major complications to treatment, often causing patients to succumb to their illness.

Read more


Inventing ways to escape from ESKAPE!!

We at Polyamyna Nanotech Inc. (PNI), endeavor to develop next-generation antimicrobial technologies to prevent infections caused by deadly pathogens, especially ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens, eventually striving to address the global antimicrobial resistance (AMR) catastrophe.


Journey like this takes a strong team!

Ramesh Kumar Mani

Co-founder, PNI

Ramesh has obtained his Ph.D. from the Memorial University of Newfoundland, Canada. He possesses over twelve years of academic and industrial experience in developing innovative polymeric and bioceramic composites for tissue engineering and implant coating applications.

Kishan Gorityala

Co-founder, PNI

Kishan holds Ph.D from Nanyang Technological University, Singapore. He has rich research experience in antibacterial drug discovery. He successfully developed novel new antibiotic molecules, which overcome the resistance against Gram-negative bacteria.

Prof. George Zhanel

Professor: Dept. of Medical Microbiology/Infectious Diseases, Max Rady College of Medicine, University of Manitoba (1987 –present) and

Coordinator: Antimicrobial Resistance Program, Departments of Medicine and Microbiology, Health Sciences Centre and

Director: Canadian Antimicrobial Resistance Allia

Read more

Charles “Chuck” Love

Charles “Chuck” Love is the founder and CEO of Venture Sciences Group (VSG). Prior to VSG, Chuck held strategic executive roles for companies pursing cutting-edge medical technologies including the Medtronic CoreValve transcatheter heart valve, Circulite Synergy ventricular assist system, and Endologix Nellix

Read more

latest news

  • Nov 2018: Our story published on CBC, NL  

  • Oct 2018: Polyamyna has been awarded InnovateNL Proof of Concept grant.

  • July 2018: Polyamyna awarded with MITACS Accelerate funding to carry out research and training.

  • May 2018: Polyamyna awarded with Embryo grant by Hacking Health, NL and NATI (Newfoundland and Labrador Association of Technology Industries) for the development of healthcare innovations.

  • April 2018: Polyamyna received NRC-IRAP grant for the development of highly-efficient antimicrobial technologies.

  • January 2018: Polyamyna has been accepted into Genesis’s Enterprise program.

Latest from the blog

02 Dec 18

Researchers very recently may have scratched the surface of another weapon in the superbug arsenal of resistance

read more

19 Nov 18

Antimicrobial resistance (AMR) and Multi Drug Resistance (MDR) are the two terms that depicts the near ghastly future

read more

17 Nov 18

This week is World Antibiotic Awareness Week, an initiative by the W

read more

02 Nov 18

Less than a generation ago, the first antibiotics were introduced as a medical treatment and it revolutionized the field of medicine. In the pre-an

read more


  • Materials Engineer/Chemist – Work term student

    Position: 1

For more updates follow us on twitter